BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26772203)

  • 21. Differential expression of RON in small and non-small cell lung cancers.
    Kanteti R; Krishnaswamy S; Catenacci D; Tan YH; EL-Hashani E; Cervantes G; Husain AN; Tretiakova M; Vokes EE; Huet H; Salgia R
    Genes Chromosomes Cancer; 2012 Sep; 51(9):841-51. PubMed ID: 22585712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
    Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer.
    Wei SJ; Yang IH; Mohiuddin IS; Kshirsagar GJ; Nguyen TH; Trasti S; Maurer BJ; Kang MH
    Biochim Biophys Acta Gene Regul Mech; 2023 Jun; 1866(2):194939. PubMed ID: 37116859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
    Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
    Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seeking New Approaches to Patients With Small Cell Lung Cancer.
    Pietanza MC; Zimmerman S; Peters S; Curran WJ
    Am Soc Clin Oncol Educ Book; 2016; 35():e477-82. PubMed ID: 27249756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
    Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
    Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer.
    Yu J; Wang S; Zhao W; Duan J; Wang Z; Chen H; Tian Y; Wang D; Zhao J; An T; Bai H; Wu M; Wang J
    Clin Cancer Res; 2018 May; 24(9):2148-2158. PubMed ID: 29437792
    [No Abstract]   [Full Text] [Related]  

  • 31. Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways.
    Wan J; Wu W
    J Exp Clin Cancer Res; 2016 Jul; 35(1):119. PubMed ID: 27456341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
    Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
    Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study.
    Alves Rde C; Meurer RT; Roehe AV
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2021-5. PubMed ID: 25012251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
    Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
    Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.
    Rudin CM; Durinck S; Stawiski EW; Poirier JT; Modrusan Z; Shames DS; Bergbower EA; Guan Y; Shin J; Guillory J; Rivers CS; Foo CK; Bhatt D; Stinson J; Gnad F; Haverty PM; Gentleman R; Chaudhuri S; Janakiraman V; Jaiswal BS; Parikh C; Yuan W; Zhang Z; Koeppen H; Wu TD; Stern HM; Yauch RL; Huffman KE; Paskulin DD; Illei PB; Varella-Garcia M; Gazdar AF; de Sauvage FJ; Bourgon R; Minna JD; Brock MV; Seshagiri S
    Nat Genet; 2012 Oct; 44(10):1111-6. PubMed ID: 22941189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
    Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
    BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification.
    Shivapurkar N; Reddy J; Matta H; Sathyanarayana UG; Huang CX; Toyooka S; Minna JD; Chaudhary PM; Gazdar AF
    Oncogene; 2002 Dec; 21(55):8510-4. PubMed ID: 12466971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification and expression of the c-myc oncogene in human lung cancer cell lines.
    Little CD; Nau MM; Carney DN; Gazdar AF; Minna JD
    Nature; 1983 Nov 10-16; 306(5939):194-6. PubMed ID: 6646201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.